IRCT2016042023559N3已完成2 期
asix effect in two ways at once and infusion therapy in patients with a kidney transplant in Imam Reza Hospital Tabriz
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15 years 至 65 years（—）
- 性别
- All
入选标准
- •Included criteria: diagnosis of ESRD, indicated for kidney transplants; admission in Tabriz Imam Reza Hospital; male and female gender; 15-65 years old.
- •Excluded criteria: patients with severe psychiatric problems; metastatic cancer patients; patients over 65 years old; patients with hemodynamic changes following their transplantation (reducing blood pressure less than 50 / 80 for more than half an hour); the constant drug abuse; chronic liver disease; reversible urinary tract infections; anomalies of the urinary system; aeortoiliac disease.
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
akritsin ja tiatsididiureetin yhteiskäytön vaikutus kaliumpitoisuuteen - Lakritsi ja hypokalemiaEUCTR2007-005717-19-FIOulu University Hospital Department of Internal Medicine
尚未招募
4 期
The effectiveness of azithromycin alone and azithromycin plus cefixime for the treatment of typhoid fever in South Asia has been studied.CTRI/2021/10/037047The University of Oxford
进行中（未招募）
1 期
AXITINIB (AG 013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIARenal cell carcinomaMedDRA version: 15.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-001451-21-DEPfizer Inc.,235 East 42nd Street,New York,NY 10017 US723
进行中（未招募）
不适用
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENALCELL CANCER: AXIS TRIAMedDRA version: 9.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinomaRenal cell carcinomaEUCTR2008-001451-21-IEPfizer Inc.,235 East 42nd Street,New York,NY 10017540
进行中（未招募）
1 期
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENALCELL CANCER: AXIS TRIARenal cell carcinomaEUCTR2008-001451-21-FRPfizer Inc.,235 East 42nd Street,New York,NY 10017540